An interventional study of Factual messages and Narrative message in Vaccination Refusal and COVID-19, sponsored by Johns Hopkins Bloomberg School of Public Health. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-10.
Sponsored by Johns Hopkins Bloomberg School of Public Health · Not applicable, Interventional, and Other
Brief Summary: The main objective of this activity is to assess the effectiveness of different messaging strategies (factual, narrative, mixed and a control) to promote COVID-19 adult vaccination.
The investigators deploy mobile phone surveys using Interactive Voice Response (IVR) in a random sample of mobile phone numbers (random digit dialing or RDD) in Colombia.
Adult individuals who have not been fully vaccinated against COVID-19 (defined as those who 1) did not get any vaccine; 2) did not get the complete vaccination scheme 3) did not get one booster when less than 50 years old; 4) did not get two boosters when older than 50 years old), and who consent to be recontacted are invited to participate in the messaging trial. After consent, participants are randomized in three different treatment arms or one control arm. Participants in each treatment arm are presented with different messages to improve COVID-19 vaccination. Participants in the arm with factual messages listen to actual data and scientifical information on COVID-19 vaccination. Those in the narrative arm listen to messages appealing to emotions drawing on the COVID-19 vaccination experiences that were explored in a qualitative study conducted earlier. The mixed arm combines both factual and narrative messages. Finally, the control arm does not deliver any message and will only ask for whether the participant got vaccinated in the last two weeks. Individuals in each of the three treatment arms receive seven different types of messages. Each message is delivered twice every week for seven weeks and their vaccination status is inquired in the same calls to assess whether the participants received their vaccine after the last call. IN all arms, respondents are asked a simple question to test the attention they pay to the information provided in the message. The three treatment arms are compared against the control to assess the probability that any of the arms is significantly better than the control. With this aim, the minimum target sample size for each messaging group is N=173 which allows for the detection of a difference between groups of at least 15% with a double-tailed distribution at alpha=0.05 and power =0.8.
The investigators launched a first cohort on September 21, 2022 over sampling both the treatment and control arms to reduce the risk of attrition and aiming at obtaining 250 recruited participants that agree to participate. Due to high attrition, a second cohort was deployed on October 25, 2022 following the same procedure as for the first cohort, this time with a target of 400 recruited respondents with the aim of achieving the required sample size.
The investigators assess the differential likelihood of vaccinating during the trial for individuals participating in the different arms, including the control.
928 studies on the registry are indexed under Coronavirus Infections; 49 are open to participants now.
This study's enrollment of 2,409 is above the median of 105 across 540 interventional studies indexed under Coronavirus Infections.
Browse Coronavirus Infections studies →Johns Hopkins Bloomberg School of Public Health is the lead sponsor of 364 studies on the registry; 41 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants in the arm with factual messages will listen to actual data on vaccination.
Behavioral: Factual messages
Participants the narrative messages will listen to messages appealing to emotions that were explored in a qualitative study conducted earlier.
Behavioral: Narrative message
The mixed arm will combine both factual and narrative messages.
Behavioral: Mixed message
Participants in the control arm will not be provided with a message and will only be asked for whether they participant got vaccinated in the last two weeks.
Messages with descriptive data on COVID-19 vaccines
Messages with emotional descriptions on COVID-19 vaccines
Messages with both descriptive data and emotional descriptions on COVID-19 vaccines
Percentage point change on the probability of new vaccination for treatment arms vs. control
The participant reports to have been vaccinated against COVID-19 in the last two weeks
Time frame: 7 weeks
Percentage point change on the probability of new vaccination conditional on correct answer to the test
The participant reports to have been vaccinated against COVID-19 in the last two weeks and also has a high score on the response to the tests after the message
Time frame: 7 weeks
Percentage point change on the probability of new vaccination conditional on demographic, socioeconomic and health characteristics
The participant reports to have been vaccinated against COVID-19 in the last two weeks and that likelihood is related to specific demographic, health and socioeconomic variables captured
Time frame: 7 weeks
Percentage of attrition between each of the different waves of messages.
Participants enrolling in the trial, decide to stop participating at any time. The likelihood of participation is assessed in correlation with sociodemographic variables.
Time frame: 7 weeks
Plan to share: No — IPD will only be analyzed by the Johns Hopkins team in an anonymized manner. Other researchers will have access only to aggregated information. No attempts to obtain identifiable information will be done and the numbers will be deleted from the main database once completed the data collection
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johns Hopkins Bloomberg School of Public Health